PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2426935122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Andres Chang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Programmed Cell Death 1 Receptor, Agammaglobulinaemia Tyrosine Kinase, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | National Institutes of Health (NIH), American Society of Hematology (ASH), EU | Winship Cancer Institute (Winship Cancer Institute of Emory University).
Abstract (Originalsprache)
Chronic lymphocytic leukemia (CLL) remains incurable despite treatment advances, and a major challenge is that biomarkers that predict response and resistance to current therapies are lacking. We report that activated and proliferating malignant CLL B cells in circulation express PD-1, a protein normally expressed in T cells. PD-1 expression is absent in circulating B cells from healthy controls and nonmalignant B cells from patients with CLL. Circulating PD-1 + CLL cells are found in all treatment naïve patients, regardless of immunoglobulin heavy-chain variable region gene mutation status or cytogenetic abnormalities. PD-1 + CLL cells are transcriptionally distinct compared to PD-1 − CLL cells and upregulate genes associated with cell activation, proliferation, and B cell receptor (BCR) and toll-like receptor (TLR) signaling. Indeed, ex vivo stimulation of the BCR and TLR9 readily increased PD-1 expression in CLL cells from treatment-naïve patients within 24 h, an effect that was blocked by Bruton’s tyrosine kinase inhibitors (BTKi). More importantly, patients initiating BTKi therapy experienced profound reductions in circulating PD-1 + CLL cell numbers within 1 mo, which is in line with reduction in Ki-67 + CLL cells. Elevated percentages of circulating PD-1 + CLL cells also preceded a clinical diagnosis of disease progression in patients receiving BTKi. Thus, our findings indicate that PD-1 expression is a potential biomarker to identify proliferating CLL cells in vivo and will be useful to predict response and resistance to BTKi. In addition, eliminating PD-1 + CLL cells with depleting anti-PD-1 monospecific or bispecific antibodies should be explored as a potential therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
- Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
- Institute of Applied Biosciences at the Centre for Research and Technology Hellas, Thessaloniki 57001, Greece.
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322.
ORCID-Profile: Rafick P Sekaly
Förderung
- HHS | National Institutes of Health (NIH)
- American Society of Hematology (ASH)
- EU | Winship Cancer Institute (Winship Cancer Institute of Emory University)
- Hellenic Foundation for Research and Innovation (HFRI)
- EC | ERC | HORIZON EUROPE European Research Council (ERC)
- CLL Society
- NIAID NIH HHS
Zitieren
APA
Chang, A., Pelletier, A. N., McGuire, D. J., Tsagiopoulou, M., Karipidou, M., Ayers, A., Leal, A. M. K., Churnetski, M. C., O'Leary, C. B., Switchenko, J. M., Davis, C., Frank, D. A., Koff, J. L., Cohen, J. B., Sekaly, R. P., Stamatopoulos, K., Flowers, C. R., & Ahmed, R. (2025). PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2426935122
Vancouver
Chang A, Pelletier AN, McGuire DJ, Tsagiopoulou M, Karipidou M, Ayers A, et al. PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2426935122
BibTeX
@article{Chang2025,
author = {Chang, Andres and Pelletier, Adam N and McGuire, Donald J and Tsagiopoulou, Maria and Karipidou, Maria and Ayers, Amy and Leal, Alyssa M K and Churnetski, Michael C and O'Leary, Colin B and Switchenko, Jeffrey M and Davis, Carl and Frank, David A and Koff, Jean L and Cohen, Jonathon B and Sekaly, Rafick P and Stamatopoulos, Kostas and Flowers, Christopher R and Ahmed, Rafi},
title = {PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2426935122}
}
EUVIMED